Category: 637-58-1

Wang, Li published the artcileDetermination of content of compound pramoxine hydrochloride cream by HPLC, SDS of cas: 637-58-1, the publication is Xibei Daxue Xuebao, Ziran Kexueban (2007), 37(1), 52-54, database is CAplus.

The paper established an HPLC method for the determination of content of compound pramoxine hydrochloride cream. A CLC-ODS C₁₈ column (150 mm × 4.6 mm, 5 μm) and acetonitrile-phosphate buffer solution (55:45) as the mobile phase (adjusted to pH 7.5) were used for the determination with the detection wavelength of 224 nm and the column temperature of 40°. The flow rate was 1.0 mL/min. Results showed that a linear relationship was obtained within the range of 0.2120-0.9035 mg/mL (r = 0.9999). The average recovery was 99.63% (RSD = 0.53%). In conclusion, the method was simple, sensitive, accurate and suitable for the quant. control of compound pramoxine hydrochloride cream.

Xibei Daxue Xuebao, Ziran Kexueban published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C18H26ClN3O, SDS of cas: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Hammarlund, E. R. published the artcileMethods of preparing isotonic solutions by means of graphs or tables on the basis of experimentally found iso-osmotic values, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Pharmaceutica Acta Helvetiae (1960), 593-607, database is CAplus.

Four graphical and three tabular methods for preparing isotonic aqueous solutions are described. New exptl. data is presented for 353 compounds to be used for the recommended and most practical of the methods studied for isotonicity adjustment. All the methods described may be used in practical pharmacy. The graphical methods are more accurate but consume more space than the tabular methods.

Pharmaceutica Acta Helvetiae published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Thoma, K. published the artcileColloid association and bioavailability of local anesthetics. Part 7. Partition behavior, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Pharmaceutica Acta Helvetiae (1988), 63(6), 155-9, database is CAplus and MEDLINE.

The partition coefficient was determined for 20 local anesthetics and was found to be considerably influenced by the chem. structure and the substituents present in the compounds In the system n-octanol/buffer (pH 5.7) partition coefficients between 0.05 (brufacaine-HCl) and 199.0 (chinisocaine-HCl) were found. In the system n-octanol/water they ranged between 0.003 (procaine-HCl and lidocaine-HCl) and 4.2 (oxetacaine-HCl). Raising the pH-value from 4 to 6 resulted in an increase of the partition coefficient of stadacain-HCl from 8.9 to 56.5. Raising the ionic strength from 0.2 to 1.0 of a pH 5.7 buffer increased the partition coefficient of stadacain-HCl from 30.4 to 95.3%. The addition of 5.0% NaCl to an aqueous, unbuffered solution of stadacain-HCl increased the partition coefficient from 0.36 to 27.2.

Pharmaceutica Acta Helvetiae published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C5H5BrN2, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Thoma, K. published the artcileColloid association and bioavailability of local anesthetics. Part 6. Mixed micelle formation with polysorbates, Product Details of C17H28ClNO3, the publication is Pharmaceutica Acta Helvetiae (1988), 63(4-5), 102-10, database is CAplus and MEDLINE.

For 19 surface-active local anesthetics, the binding to polyethylene glycol sorbitan fatty acid esters (I) by formation of mixed micelles was determined All surface-active local anesthetics investigated, except procaine-HCl and lidocaine-HCl, form mixed micelles with I. In the presence of 5% I in water, this binding fluctuates between 5.3% for butacaine sulfate and 75% for cyclomethycaine-sulfate. For all local anesthetics the quotient of the total concentration and the free moiety is proportional to the surfactant concentration The surfactant bound moiety of the local anesthetic is constant when it is below its critical micellar concentration (CMC). Above the CMC, deviations from this rule are observed The binding of tetracaine-HCl to I by mixed micelles formation demonstrates that the binding to these surfactants increases with the shortened fatty acid chain (that means an increasing HLB-value). When the pH-value or ionic strength increases, stadacain-HCl exhibits a distinct increase of the binding by a change of the dissociation-rate or a salting-out effect. Changing the solvent of stadacain-HCl from water to saline, for example, increases the binding to 5% I from 38.1 to 68%.

Pharmaceutica Acta Helvetiae published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C19H14N2, Product Details of C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Aleyasin, Hossein published the artcileAntihelminthic Benzimidazoles Are Novel HIF Activators That Prevent Oxidative Neuronal Death via Binding to Tubulin, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Antioxidants & Redox Signaling (2015), 22(2), 121-134, database is CAplus and MEDLINE.

Aims: Pharmacol. activation of the adaptive response to hypoxia is a therapeutic strategy of growing interest for neurol. conditions, including stroke, Huntington’s disease, and Parkinson’s disease. We screened a drug library with known safety in humans using a hippocampal neuroblast line expressing a reporter of hypoxia-inducible factor (HIF)-dependent transcription. Results: Our screen identified more than 40 compounds with the ability to induce hypoxia response element-driven luciferase activity as well or better than deferoxamine, a canonical activator of hypoxic adaptation. Among the chem. entities identified, the antihelminthic benzimidazoles represented one pharmacophore that appeared multiple times in our screen. Secondary assays confirmed that antihelminthics stabilized the transcriptional activator HIF-1α and induced expression of a known HIF target gene, p21^cip1/waf1, in post-mitotic cortical neurons. The on-target effect of these agents in stimulating hypoxic signaling was binding to free tubulin. Moreover, antihelminthic benzimidazoles also abrogated oxidative stress-induced death in vitro, and this on-target effect also involves binding to free tubulin. Innovation and Conclusions: These studies demonstrate that tubulin-binding drugs can activate a component of the hypoxic adaptive response, specifically the stabilization of HIF-1α and its downstream targets. Tubulin-binding drugs, including antihelminthic benzimidazoles, also abrogate oxidative neuronal death in primary neurons. Given their safety in humans and known ability to penetrate into the central nervous system, antihelminthic benzimidazoles may be considered viable candidates for treating diseases associated with oxidative neuronal death, including stroke. Antioxid. Redox Signal. 22, 121-134.

Antioxidants & Redox Signaling published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Shahar, Or David published the artcileA high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Nucleic Acids Research (2014), 42(9), 5689-5701, database is CAplus and MEDLINE.

DNA double-strand breaks (DSBs) are the most severe type of DNA damage. DSBs are repaired by non-homologous end-joining or homol. directed repair (HDR). Identifying novel small mols. that affect HDR is of great importance both for research use and therapy. Mols. that elevate HDR may improve gene targeting, whereas inhibiting mols. can be used for chemotherapy, since some of the cancers are more sensitive to repair impairment. Here, the authors performed a high-throughput chem. screen for FDA approved drugs, which affect HDR in cancer cells. The authors found that HDR frequencies are increased by retinoic acid and Idoxuridine and reduced by the antihypertensive drug Spironolactone. The authors further revealed that Spironolactone impairs Rad51 foci formation, sensitizes cancer cells to DNA damaging agents, to Poly (ADP-ribose) polymerase (PARP) inhibitors and crosslinking agents and inhibits tumor growth in xenografts, in mice. This study suggests Spironolactone as a new candidate for chemotherapy.

Nucleic Acids Research published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C18H12ClNO, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Varga, Janos M. published the artcileMechanism of allergic cross-reactions. I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody, Quality Control of 637-58-1, the publication is Molecular Immunology (1991), 28(6), 641-54, database is CAplus and MEDLINE.

A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE (I). All DNP-amino acids, that were tested inhibited the binding of the radio-labeled I to DNP covalently attached to polystyrene microplates; however, the concentration for 50% inhibition varied within four orders of magnitude, DNP-L-serine being the most and DNP-L-proline the least potent inhibitor. In addition to DNP analogs, a large number of drugs and other compounds were tested for their ability to compete with DNP for the binding site of I. At the concentration used for screening, 59% of compounds had no significant inhibition; 19% inhibited the binding of I more than 50%. Several families of compounds (tetracyclines, polymyxins, phenothiazines, salicylates, and quinones) that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with I is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.

Molecular Immunology published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C7H13ClNNaO5S, Quality Control of 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Shaw, Margaret A. published the artcileIsotonic solutions. XIII. Hemolysis of red corpuscles by various substances in the presence of sodium chloride, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Journal of Pharmaceutical Sciences (1962), 929-31, database is CAplus and MEDLINE.

cf. CA 58, 3735c. An increase in the concentration of NaCl reduced the degree of hemolysis produced in the presence of 0.6% NaCl by procaine-HCl, 2-propoxyprocaine-HCl, NH₄ salicylate, NH₄ benzoate, pramoxine-HCl, benoxinateHCl, hexylcaine-HCl and butacaine sulfate, but increased that produced by phenmetrazine-HCl.

Journal of Pharmaceutical Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C4H6O3, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Thoma, Karl published the artcileStudies to determine the critical micelle concentration of local anesthetics, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Acta Pharmaceutica Fennica (1984), 93(2), 85-96, database is CAplus.

The critical micelle concentrations of local anesthetics such as cyclomethycaine sulfate  [6202-05-7], Psicaine-neu-HCl  [69343-45-9], cocaine-HCl  [53-21-4], etc., were determined by using tensiometry and potentiometry and spectrophotometry of some anesthetics. The nonionic polidocanol  [9002-92-0] had a critical micellar concentrations of 1 × 10^-4 mol/L found both by tensiometry and dye sorption methods. The dissociating local anesthetics show critical micelle concentrations from 0.046-5.5% in aqueous solution

Acta Pharmaceutica Fennica published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C18H34N4O5S, Name: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Musdal, Yaman published the artcileFDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1, SDS of cas: 637-58-1, the publication is Chemico-Biological Interactions (2013), 205(1), 53-62, database is CAplus and MEDLINE.

Glutathione transferase P1-1 (GST P1-1) is often overexpressed in tumor cells and is regarded as a contributor to their drug resistance. Inhibitors of GST P1-1 are expected to counteract drug resistance and may therefore serve as adjuvants in the chemotherapy of cancer by increasing the efficacy of cytostatic drugs. Finding useful inhibitors among compounds used for other indications would be a shortcut to clin. applications and a search for GST P1-1 inhibitors among approved drugs and other compounds was therefore conducted. We tested 1040 FDA-approved compounds as inhibitors of the catalytic activity of purified human GST P1-1 in vitro. We identified chlorophyllide, merbromine, hexachlorophene, and ethacrynic acid as the most effective GST P1-1 inhibitors with IC₅₀ values in the low micromolar range. For comparison, these compounds were even more potent in the inhibition of human GST A3-3, an enzyme implicated in steroid hormone biosynthesis. In distinction from the other inhibitors, which showed conventional inhibition patterns, the competitive inhibitor ethacrynic acid elicited strong kinetic cooperativity in the glutathione saturation of GST P1-1. Apparently, ethacrynic acid serves as an allosteric inhibitor of the enzyme. In their own right, the compounds investigated are less potent than desired for adjuvants in cancer chemotherapy, but the structures of the most potent inhibitors could serve as leads for the synthesis of more efficient adjuvants.

Chemico-Biological Interactions published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, SDS of cas: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem